Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial health with high gross margins and a positive ROI on DTC campaigns. Despite some uncertainties in guidance specifics, the management's confidence in reaching a $2 billion sales target, ongoing international expansion, and a positive outlook for pipeline developments suggest optimism. The Q&A highlights potential growth despite seasonal disruptions, and no major expense increases beyond 2026. These factors, combined with strong market penetration and execution, indicate a positive sentiment, likely leading to a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Full Year Net Sales $451.4 million, with a gross to net discount of approximately 45%. This represents a significant achievement, driven by the successful launch and adoption of XDEMVY.
Fourth Quarter Net Product Sales $151.7 million, with a gross to net discount of 44%. This reflects strong quarterly performance and continued growth in product adoption.
Total Operating Expenses $522.3 million, primarily driven by commercial investments supporting the XDEMVY launch.
Cash, Cash Equivalents, and Marketable Securities Approximately $418 million at the end of the year, providing financial flexibility for scaling the business and expanding the pipeline.
Gross Margins Approximately 93%, indicating strong profitability from product sales.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
XDEMVY: First and only FDA-approved therapeutic for Demodex blepharitis, achieving over $450 million in net sales in 2025 and helping over 0.5 million patients. Expected to reach blockbuster status with sales potential exceeding $2 billion.
TP-04 for Ocular Rosacea: Initiated Phase II trial in December 2025 for Ocular Rosacea, a condition affecting 15-18 million Americans with no FDA-approved treatments. Top-line data expected in the first half of 2027.
TP-05 for Lyme Disease Prevention: Phase II trial to begin in Q2 2026, targeting 700 participants. Aims to address a significant unmet need with no current FDA-approved preventative therapies. Top-line data expected in the first half of 2027.
U.S. Market Expansion for XDEMVY: Sales potential exceeding $2 billion, supported by 90% coverage across commercial, Medicare, and Medicaid. Increased patient awareness and proactive demand for the product.
Global Expansion for TP-03: Regulatory approval expected in Europe by 2027, ongoing discussions in Japan, and potential approval in China by the end of 2026.
Sales Force Expansion: Plan to add 15-20 key account leaders in 2026 to deepen market penetration and support high-opportunity practices.
Direct-to-Consumer Campaign: Maintaining 2025 spending levels while focusing on high-return channels. Campaign has increased unaided awareness of XDEMVY from 2% to 25%.
Pipeline Expansion: Targeting 1-2 new programs per year to ensure focused growth and efficient capital allocation.
Leadership Addition: Appointment of David Pyott, former CEO of Allergan, to the Board of Directors to leverage his expertise in scaling global eye care franchises.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Risks: Potential delays or challenges in obtaining regulatory approvals for TP-03 in Europe, Japan, and China, as well as for other pipeline products like TP-04 and TP-05.
Pipeline Development Costs: High costs associated with clinical trials, such as the $25-$30 million for the Phase II trial of TP-05 for Lyme disease prevention, which could strain financial resources.
Market Penetration Challenges: Despite strong initial sales, there is still a large untapped market of 25 million Americans with Demodex blepharitis, indicating potential challenges in reaching and converting these patients.
Seasonality and Revenue Fluctuations: Revenue growth is not linear and is impacted by seasonality, deductible resets, and external factors like severe weather, which could affect financial performance.
Competitive Pressures: Emerging competition in the eye care and biotech sectors could impact market share and pricing power for XDEMVY and other products.
Supply Chain and Operational Risks: Potential disruptions in the supply chain or operational inefficiencies could impact the production and distribution of XDEMVY and other pipeline products.
Economic and Consumer Behavior Risks: Economic uncertainties and changes in consumer behavior could impact patient willingness to seek treatment or afford medications, despite insurance coverage.
Clinical Trial Risks: Uncertainty in clinical trial outcomes for pipeline products like TP-04 and TP-05, which could delay or derail product launches.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
XDEMVY Sales Projections: The company expects XDEMVY to reach blockbuster status within the next couple of years, with sales potential exceeding $2 billion. For 2026, net product sales are projected to be in the range of $670 million to $700 million, representing annual growth of more than $230 million and 50% at the midpoint of guidance.
Market Expansion and Growth Drivers: The company plans to expand its sales force by adding 15 to 20 key account leaders in 2026 to increase depth within high-opportunity practices. Additionally, targeted investments in clinical and real-world data generation, as well as direct-to-consumer campaigns, are expected to drive growth.
Pipeline Development: The company is advancing TP-04 for Ocular Rosacea, with a Phase II trial initiated in December 2025 and top-line data expected in the first half of 2027. TP-05 for Lyme disease prevention will enter a Phase II trial in Q2 2026, with top-line data also expected in the first half of 2027. TP-03 is on track for potential regulatory approval in Europe in 2027, with progress in Japan and China as well.
Revenue Seasonality: Revenue growth in 2026 is not expected to be linear. The first quarter is anticipated to be flat or slightly below Q4 2025 revenue due to seasonality, including deductible resets and weather disruptions. Sequential growth is expected to follow a pattern similar to 2025, with strong growth in Q2, tempered growth in Q3, and robust growth in Q4.
Profitability and Financial Strategy: XDEMVY is already profitable from a product line perspective. The company expects increasing operating leverage as revenue scales, with a clear line of sight toward potential company-level profitability. Gross margins are expected to remain strong at approximately 93% in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give more detail about the expectations beyond Q1 for the $370 million to $400 million guidance, particularly regarding bottles and refill cadence?
A:Management expects flat to slightly down performance in Q1 due to deductible resets, a bump in Q2, tempered growth in Q3, and robust growth in Q4 due to FSAs and deductible expirations. They will not provide specific bottle or gross-to-net guidance unless there is a material change.
Q:Do seasonal disruptions like conferences, weather, and holidays continue to impact the launch as docs and patients get more familiar with administration and refills?
A:Seasonal disruptions will continue to impact the launch as the brand becomes more susceptible to typical seasonality. However, management is confident in the brand's growth due to a strong prescriber base, consumer awareness, and refills. The long-term outlook remains positive.
Q:Where do you see the steady-state gross-to-net settling out for 2026, and are there favorable dynamics offsetting Q1 pressures?
A:The gross-to-net discount is expected to settle at 43%-45%, with a stepwise decrease in Q2 and reaching the lower end of the range by mid-year. Q1 pressures are typical, but no specific favorable dynamics were highlighted.
Q:What is driving the increased conviction in the $2 billion peak sales target?
A:The increased conviction is driven by the product's performance, less than 10% market penetration, transformation of eye care practices, and flawless execution in commercial efforts, education, access, and evidence.
Q:Is it worth investing more in the DTC campaign given its positive ROI?
A:The DTC campaign has performed exceptionally well, achieving positive ROI earlier than expected. Management believes $80 million is the right level of spend, with incremental investment in the sales force to support prescribing and utilization.
Q:Can you provide details on the Lyme disease program study?
A:The Phase IIb trial will enroll 700 participants in one peak season, focusing on safety and blood levels of lotilaner to build a Phase III-ready package and provide directional input for a Phase III study.
Q:Would operating expenses continue to step up beyond 2026?
A:No major step-ups are expected beyond 2026, except for variable costs tied to revenue increases and potential adjustments in DTC spend in 2027 and beyond.
Q:Can you elaborate on the opportunities in European, Japanese, and Chinese markets for the preservative-free formulation?
A:The dynamics in these markets are similar to the U.S., with consistent disease prevalence and treatment paradigms. Positive U.S. experiences are generating interest, and pricing and reimbursement dynamics will dictate the go-to-market approach.
Q:When do you expect to achieve the $2 billion peak sales target, and is there room beyond 2032?
A:It is too early to specify when the $2 billion peak will be achieved, but growth remains strong. There is potential beyond 2032 based on secondary patents extending to 2038.
Q:What is a meaningful trend on erythema in the ocular rosacea program, and is there a scenario to hit statistical significance?
A:The program focuses on objective improvements in erythema and telangiectasia, with alignment from the FDA. Any improvement is meaningful to eye care professionals, and the data will guide further discussions with the FDA.
Q:Can you provide additional insight into seasonal trends and the cost of pivotal studies for ocular rosacea and Lyme disease?
A:Seasonal trends include deductible resets and weather impacts, with positive trajectory expected post-Q1. The ocular rosacea study is estimated to cost $7-$10 million, and the Lyme disease study $25-$30 million, mostly incurred in 2026.
Q:What are the current prescribing trends for XDEMVY between ophthalmologists and optometrists?
A:Prescribing is split roughly 2/3 optometry and 1/3 ophthalmology, with strong growth in both segments. Depth of prescribing is increasing, with 40% of core targets prescribing weekly and 20% growth in daily writers.
Q:What is the U.S. versus ex-U.S. split for the $2 billion peak sales guidance?
A:The $2 billion peak sales guidance is specific to the U.S. Ex-U.S. markets are estimated to contribute about 10% of total sales, with Japan potentially offering a higher opportunity than Europe.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on bottle numbers and gross-to-net figures, stating they would only comment on material changes. Additionally, they did not specify when the $2 billion peak sales target would be achieved, citing it as too early to determine.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Americans
CEO
Chief Officer
II trial
III package
Lyme disease
Phase II
Phase III
Rosacea
TP lotilaner
TP potential
Today
account leader
afternoon
biology need
care experience
category eye
confidence TP
development
expertise
flexibility
framework
improvement
infrastructure
leverage
medicine
outcome
playbook
potential TP
prevention
product line
proof point
risk Lyme
screening
seasonality
standard care
stock compensation
tick
trial TP
TARS Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights a solid financial performance with a 20% revenue increase and improved gross margins. Despite increased operating expenses, net income rose, indicating effective cost management. The company's profitability and cash flow growth are positive indicators. However, the absence of strategic or operational updates and acknowledgment of risks in forward-looking statements slightly tempers the outlook. Overall, the financial results are strong enough to predict a positive stock price movement over the next two weeks, especially given the 25% increase in cash flow and robust demand for the lead product.
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call reveals strong financial health with high gross margins and a positive ROI on DTC campaigns. Despite some uncertainties in guidance specifics, the management's confidence in reaching a $2 billion sales target, ongoing international expansion, and a positive outlook for pipeline developments suggest optimism. The Q&A highlights potential growth despite seasonal disruptions, and no major expense increases beyond 2026. These factors, combined with strong market penetration and execution, indicate a positive sentiment, likely leading to a stock price increase of 2% to 8% over the next two weeks.
TARS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
